A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-30

Study Completion Date

2023-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of LPCN 1148 in men with cirrhosis of the liver and sarcopenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis

NCT04134091

Nonalcoholic Steatohepatitis (NASH)

COMPLETED PHASE2

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

NCT04685993

NASH - Nonalcoholic Steatohepatitis

COMPLETED PHASE2

Study in Healthy Adults Evaluating PF-07202954

NCT04857437

Non-Alcoholic Fatty Liver Disease Liver Fibrosis

COMPLETED PHASE1

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254

Compensated Cirrhosis Nonalcoholic Steatohepatitis

COMPLETED PHASE3

Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects

NCT05737433

NASH With Fibrosis

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a 52-week, multicenter, double-blind, placebo-controlled, two arm study of LPCN 1148 in adult men with cirrhosis of the liver and sarcopenia on the liver transplant waitlist. This study will evaluate the efficacy, safety, and tolerability of LPCN 1148, determined through a range of clinical outcomes and functional and laboratory tests.

Approximately 48 subjects will be randomized 1:1 ratio to receive one of the following treatments:

* Treatment A: Oral LPCN 1148
* Treatment B: Oral matching placebo.

Subjects will undergo a screening period to determine study eligibility. Adult male subjects with liver cirrhosis and sarcopenia on the transplant list will be enrolled into the study.

There are two treatment phases to this study.

* Stage 1: 24 weeks of blinded study treatment (LPCN 1148 or matching placebo)
* Stage 2: 28-week open-label extension. Subjects who participate in Stage 1 of this trial will roll over to a 28-week open-label extension phase. All subjects will receive LPCN 1148; there will be no placebo in the extension period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized 1:1 to LPCN 1148 or placebo

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LPCN 1148

Oral LPCN 1148 capsules, administered as BID.

Group Type EXPERIMENTAL

LPCN 1148

Intervention Type DRUG

LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.

Placebo

Oral matching placebo capsules, administered as BID.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral matching placebo capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LPCN 1148

LPCN 1148 is an oral capsule product containing an ester prodrug of bioidentical testosterone, designed to enable absorption via intestinal lymphatics.

Intervention Type DRUG

Placebo

Oral matching placebo capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male ≥ 18 years old
2. Currently listed, on the liver transplant waitlist for cirrhosis secondary to Hepatitis B or C infection, Alcoholic Liver Disease (ALD), Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC), or Primary Sclerosing Cholangitis (PSC)
3. Evidence of sarcopenia with appropriate cutoff recommended by clinical guidance

Exclusion Criteria

1. Suspected or proven hepatocellular carcinoma (HCC)
2. History of current or suspected prostate or breast cancer
3. History of malignancies other than prostate, breast, or HCC, unless successfully treated with curative intent and believed to be cured (defined as complete remission lasting at least 5 years)
4. History of uncontrolled or recurrent portal hypertensive bleeding, including uncontrolled or recurrent bleeding from varices, gastropathy, colopathy, or hemorrhoidal bleeding in the past 6 months.
5. History or current thrombosis (including portal vein thrombosis), thromboembolism, or treatment for portal vein thrombosis
6. History of hemochromatosis
7. History of hypercoagulable state (e.g. Factor V Leiden deficiency, protein C deficiency, protein S deficiency, anti-thrombin III deficiency, or the presence of lupus anticoagulant)
8. Prior history of complications of ascites in the past 6 months including:

1. Spontaneous bacterial peritonitis
2. Hepatic hydrothorax
9. MELD score \> 25
10. Abnormal lab value in serum chemistry, hematology, or urinalysis that the PI considers clinically significant, including but not limited to:

1. PSA \> 4 ng/mL
2. Polycythemia (Hematocrit \> ULN) or history of polycythemia
3. ALT or AST \> 5x ULN
4. ALP \> 2x ULN; subjects with PBC or PSC are excluded if ALP is \> 10x ULN
5. Platelet count \< 30,000/mL
6. EGFR \< 30 mL/min/1.73 m2 for subjects not undergoing routine, scheduled dialysis
7. Serum albumin \< 2.0 g/dL
8. INR \> 2.3
11. Subjects with PSA between 2.5 ng/mL and 4 ng/mL are excluded only if any of the below criteria are met at baseline:

1. Hematocrit \> 48%
2. I-PSS \> 19
3. Any irregularity found on digital rectal examination of the prostate
12. Subjects with PSA \> 3 ng/mL are excluded only if any of the below criteria are met at baseline:

1. Subject is African American
2. Subject has a first-degree relative who has a history of prostate cancer
3. Hematocrit \> 48%
4. I-PSS \> 19
5. Any irregularity found on digital rectal examination of the prostate
13. Clinically significant abnormal prostate digital rectal examination (DRE) in the opinion of the PI, with DRE screening initiated at International Prostate Symptom Score (I-PSS) \> 19
14. History of bariatric surgery
15. History of stroke or myocardial infarction within the past 5 years
16. History of TIPS within the past 6 months, or TIPS procedure expected within 6 months of Day 1
17. Known positivity for Human Immunodeficiency Virus (HIV) infection
18. Acute liver failure as the indication for addition to the liver transplant waitlist
19. Estimated life expectancy less than 3 months or expected to undergo liver transplant within 3 months
20. Known heart failure of New York Heart Association class III or IV
21. Evidence of severe encephalopathy at screening encephalopathy that is not controlled despite adequate medical therapy
22. History of prior organ transplant
23. History of Fontan physiology
24. History of pulmonary embolus
25. Porto-pulmonary hypertension
26. Hepatopulmonary syndrome requiring standing home supplemental oxygen therapy, or MELD exception points for hepatopulmonary syndrome
27. Uncontrolled epilepsy or migraine
28. Active substance abuse or dependency extending to within the previous 3 months
29. History of significant sensitivity or allergy to testosterone, or product excipients.
30. Use of known strong inhibitors (e.g., ketoconazole) or inducers (e.g., dexamethasone, phenytoin, rifampin, carbamazepine) of cytochrome P450 3A (CYP3A) within 30 days prior to study drug administration and through the end of the study
31. Subjects who are currently receiving any androgens (testosterone or other androgens or androgen-containing supplements) and are unwilling to washout prior to screening

a. Washout: 12 weeks following long-acting intramuscular androgen injections; 4 weeks following topical or buccal androgens; 3 weeks following oral androgens
32. Uncontrolled hypertension (\>160/90 mmHg despite treatment)
33. Uncontrolled obstructive sleep apnea
34. Use of any investigational drug within 5 half-lives of the last dose or in the past 6 months prior to Study Day -2 without medical monitor and/or Sponsor approval
35. Subject who is not willing to use adequate contraception for the duration of the study
36. Any other condition, which in the opinion of the investigator would impede compliance to the study protocol (including diet, exercise, and alcohol abstinence) or hinder completion of the study
37. Failure to give informed consent

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No